Valeant Pharmaceuticals International Inc
featured
The "Fast Money" traders share their final trades of the day.
» Read More
More
-
The "Fast Money" traders share their final trades of the day.
-
The Parsippany, N.J., company's stock had already climbed about 16 percent since last Friday, when Actavis and Irish drugmaker Warner Chilcott PLC said that they were in early talks about a possible combination but had reached no agreement yet. Actavis shares rose 62 cents to $124.50 in premarket trading about 40 minutes ahead of Thursday's market opening.
-
Actavis received and rejected a takeover offer from Mylan last week that valued the generic drugmaker at more than $15 billion, a person familiar with the situation said.
-
May 2- Valeant Pharmaceuticals International Inc:. *Says intends to vigorously contest Anacor's claims and continues to expect to. launch the product in 2013* Source text for Eikon* Further company coverage ().
-
*TSX rises 58.35 points, or 0.47 percent, to 12,379.64. TORONTO, May 2- Financial shares pushed Canada's main stock index higher on Thursday after the European Central Bank cut interest rates and insurers Manulife Financial Corp.
-
TORONTO, May 2- Canada's main stock index was little changed on Thursday as weakness in some healthcare and material stocks after weak earnings reports offset optimism following a move by the European Central Bank to cut interest rates. The market was disappointed by results from Goldcorp Inc.
-
TORONTO, May 2- Canada's main stock index turned negative in early Thursday trade, hurt by weakness in materials and energy stocks, as well as declines in healthcare companies Catamaran Corp. The Toronto Stock Exchange's S&P/TSX composite index. was down 39.95 points, or 0.32 percent, at 12,281.34, after opening higher.
-
Wall Street was set to open slightly higher Thursday as an interest rate cut from the European Central Bank and better-than-expected weekly jobless claims data in the U.S. boosted investors' appetite for risky assets. **GENERAL MOTORS CO, Wednesday close $30.18, up 4 pct premarket. **VISA INC, Wednesday close $166.02, up 3 pct premarket.
-
*Sees 2013 cash EPS $5.55- $5.85 vs prior fcast $5.45- $5.75. The fast-growing drugmaker said it now expected an adjusted 2013 profit, which it calls cash earnings, of between $5.55 and $5.85 per share, up from its previous forecast of $5.45 to $5.75.
-
**GENERAL MOTORS CO, Wednesday close $30.18, up 4 pct premarket. **SEAGATE TECHNOLOGY, Wednesday close $36.94, up 4 pct premarket. **FACEBOOK INC, Wednesday close $27.43, up 2 pct premarket.
-
May 2- Canada's main stock index is set to open higher after the European Central Bank cut interest rates by 25 basis points as inflation in the euro zone fell below its target. *Catamaran Corp reported a higher-than-expected first-quarter profit, helped by the $4.4 billion acquisition of rival Catalyst Health Solutions.
-
WINNIPEG, Manitoba, May 2- Valeant Pharmaceuticals International Inc Chief Executive Michael Pearson said on Thursday that the company would focus on acquisitions with strong cash flow in high growth areas, avoiding western Europe and Japan, where big pharmaceutical companies dominate.
-
**GENERAL MOTORS CO, Wednesday close $30.18. **MANULIFE FINANCIAL CORP, Wednesday close $14.65. **ACTAVIS INC, Wednesday close $104.39.
-
**A private equity group made up of Bain Capital LLC and Golden Gate Capital Corp has emerged as the lead contender to buy BMC Software Inc for more than $6.5 billion, three people familiar with the matter said on Tuesday.
-
May 1- Generic drugmaker Actavis Inc bought the global rights to Canadian firm Valeant Pharmaceuticals International Inc's antibiotic vaginal gel for about $55 million.
-
*Under the terms of the agreement, Actavis specialty brands is acquiring the. product for approximately $55 million. *$55 million includes upfront and certain milestone payments, minimal.
-
*Actavis would take Valeant outside its area of expertise. WINNIPEG/ NEW YORK, April 30- After five years and some 60 deals that have turned Valeant Pharmaceuticals International Inc into a stock market darling with a market capitalization of $22 billion, Chief Executive Michael Pearson still has some surprises up his sleeve.
-
*Actavis would take Valeant outside its area of expertise. WINNIPEG/ NEW YORK, April 30- After five years and some 60 deals that have turned Valeant Pharmaceuticals International Inc into a stock market darling with a market capitalization of $22 billion, Chief Executive Michael Pearson still has some surprises up his sleeve.